Keros Therapeutics
KROS
49 hedge funds and large institutions have $454M invested in Keros Therapeutics in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 8 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
11% more capital invested
Capital invested by funds: $410M → $454M (+$44.5M)
4.18% more ownership
Funds ownership: 54.22% → 58.41% (+4.2%)
4% less funds holding
Funds holding: 51 → 49 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$47.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$3.31M |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$1.01M |
| 5 |
Goldman Sachs
New York
|
+$703K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.26M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.51M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.84M |
KROS Hedge Fund Activity: Q3 2020 in Review
49 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2020, worth a combined $454M — up 11% from $410M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of KROS and 6 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 17 added.
The largest buyer was Logos Global Management, adding an estimated $47.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $11.3M sold.
- 49 institutional investors held Keros Therapeutics (KROS) as of Q3 2020, down from 51 in Q2 2020.
- Funds reported $454M of Keros Therapeutics stock for Q3 2020, up 11% quarter-over-quarter.
- 6 funds opened new Keros Therapeutics positions in Q3 2020 and 8 closed out, a net change of -2 holders.
- The largest Keros Therapeutics buyer in Q3 2020 was Logos Global Management, an estimated $47.6M added.
- The largest Keros Therapeutics seller in Q3 2020 was Deerfield Management, an estimated $11.3M sold.
Based on aggregated 13F filings for Q3 2020.